Cervical cancer does not announce itself loudly. In its earliest stages, it is often silent-causing no pain, bleeding or obvious warning signs. Many women live with the disease for months, sometimes years, unaware that cancer is quietly advancing in their bodies.
Play Video
By the time symptoms such as abnormal vaginal bleeding, unusual discharge, persistent back pain or changes in bowel habits appear, the disease is often already at an advanced and far more dangerous stage. This silence is one of cervical cancer’s greatest risks and one of Kenya’s most urgent public health challenges.
Today, cervical cancer claims approximately 10 Kenyan women’s lives every single day. It is the leading cause of cancer-related deaths among women in the country and the second most common cancer after breast cancer.
According to the 2022 Kenya Demographic and Health Survey (KDHS), without decisive intervention, daily deaths could more than double to 22 by 2040.
These figures are not abstract. They represent mothers, daughters, professionals, caregivers and breadwinners lost to a disease that is largely preventable and highly treatable when detected early. Yet from a health risk perspective, late diagnosis remains the single biggest driver of poor outcomes.
In Kenya, about two-thirds of cervical cancer cases are detected only after the disease has advanced.
At this stage, treatment options are limited, more expensive and far less effective. Survival statistics tell a sobering story: the probability of surviving one year after diagnosis is about 57 percent, dropping to 45 per cent after two years.
Only around one-third of patients receive the full course of treatment they need.
Late diagnosis is closely linked to low screening rates. The KDHS shows that only 16.8 per cent of Kenyan women have ever been screened for cervical cancer.
Between 2011 and 2020, screening coverage for HIV-negative women fluctuated widely, at times falling below one per cent. For HIV-positive women-who face higher risk due to compromised immunity-coverage has remained even lower, while only a quarter of health facilities offered screening services as of 2018.
HPV vaccination, introduced in 2019, has seen first-dose coverage rise from 24 per cent in 2022 to over 60 per cent by the end of 2024, with second-dose uptake improving. The shift to a single-dose regimen in October 2025 could further accelerate coverage.
January, Cervical Cancer Awareness Month, should therefore be more than symbolic. It is a call to action for employers, insurers, healthcare providers and policymakers to expand affordable screening, strengthen workplace health programmes, improve financing solutions and ensure respectful, accessible care.